Trial Profile
An Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Neoral in Cardiac Transplant Recipients With Established Allograft Vasculopathy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2010
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary) ; Everolimus (Primary)
- Indications Heart transplant rejection
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 09 Jul 2010 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 24 Dec 2009 New trial record